Navigating Legal, Regulatory, and Intellectual Property Challenges in Advanced Drug Delivery Systems: A Multijurisdictional Analysis of Innovation, Compliance, and Patient Safety
International Journal of Drug Delivery Technology · 04.06.2026 · 16 (45s)
DOI: 10.25258/ijddt.16.45s.77 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 04.06.2026. Verfasst von Ravinderjeet Kaur und 3 weiteren Autor:innen.
Themen: Patientensicherheit
Abstract (Originalsprache)
Advanced Drug Delivery Systems (ADDS) occupy a critical nexus between pharmaceutical innovation, intellectual property law, regulatory governance, and patient safety. This paper undertakes a comprehensive multijurisdictional analysis of the legal and regulatory landscape confronting ADDS encompassing nanomedicines, liposomal formulations, targeted delivery platforms, gene therapy vectors, transdermal systems, implantable devices, and three-dimensionally printed pharmaceutical dosage forms. Drawing upon primary legislative instruments, case law from the United States, European Union, India, Japan, and South Africa, and guidance documents from the FDA, EMA, CDSCO, and PMDA, the article maps a fragmented but evolving global regulatory architecture. Particular attention is devoted to intellectual property (IP) strategies including composition-of-matter, process, and delivery-system patents alongside pernicious evergreening practices that retard generic market entry and inflate therapeutic costs in low- and middle-income countries (LMICs). The paper interrogates how compulsory licensing provisions under the TRIPS Agreement and the Doha Declaration interact with ADDS patent thickets, examining transformative jurisprudence including Novartis AG v. Union of India (2013) and Natco Pharma v. Bayer Corporation (2012). The patient safety dimension is analysed through a pharmacovigilance lens, assessing the adequacy of post-market surveillance frameworks for novel ADDS, including adverse event case studies involving nanoparticle formulations and gene therapy products. The paper concludes with a normative framework of policy recommendations directed at legislators, regulatory agencies, and innovator companies, advocating harmonised international standards, TRIPS-consistent access mechanisms, and adaptive governance architectures capable of matching the velocity of pharmaceutical innovation.
Zitieren
APA
Kaur, R., Parbhakar, D., Chahal, N. K., & Kahlon, A. (2026). Navigating Legal, Regulatory, and Intellectual Property Challenges in Advanced Drug Delivery Systems: A Multijurisdictional Analysis of Innovation, Compliance, and Patient Safety. International Journal of Drug Delivery Technology, 16(45s). https://doi.org/10.25258/ijddt.16.45s.77
Vancouver
Kaur R, Parbhakar D, Chahal NK, Kahlon A. Navigating Legal, Regulatory, and Intellectual Property Challenges in Advanced Drug Delivery Systems: A Multijurisdictional Analysis of Innovation, Compliance, and Patient Safety. International Journal of Drug Delivery Technology. 2026;16(45s). doi:10.25258/ijddt.16.45s.77
BibTeX
@article{Kaur2026,
author = {Kaur, Ravinderjeet and Parbhakar, Dev and Chahal, Navneet Kaur and Kahlon, Amanat},
title = {Navigating Legal, Regulatory, and Intellectual Property Challenges in Advanced Drug Delivery Systems: A Multijurisdictional Analysis of Innovation, Compliance, and Patient Safety},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {45s},
doi = {10.25258/ijddt.16.45s.77}
}
EUVIMED